Cannabis Science Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with Its Team of FDA Specialists



March 12, 2012 11:11 AM Eastern Daylight Time

COLORADO SPRINGS, Colo.–(EON: Enhanced Online News)–Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company       developing pharmaceutical cannabis (marijuana) products, is pleased to       announce its FDA progress resulting from the last meeting with the       Company’s FDA Specialist team to officially determine that the target       indication will be for a topical application for skin cancer.

Cannabis Science has already seen first hand success in reducing the       tumor burden in basil and squamous cell carcinoma, two forms of skin       cancer. The company website http://cannabisscience.com       photo-documents tumor shrinkage and disappearance after the       self-administration of topical cannabis extract treatment by four skin       cancer patients. As a consequence of these anecdotal observations,       Cannabis Science is confident of the need and opportunity to enter the       prescription drug market. Our advisors are preparing the required       submission for a pre-IND application to the FDA for our topical skin       cream/extract for skin cancer.

Cannabis Science is excited to pursue these investigations with the help       of our FDA specialists. Cannabis Science is overseeing additional       successes with other self-medicating cancer patients suffering from a       variety of other cancers. Reports of their progress will be made       available as treatments progress and are confirmed.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade       medical marijuana research and development. The second formulations will       address the needs of patients choosing to use concentrated cannabis       extracts to treat their ailments. Eventually, all Americans will have       access to a safe and effective FDA approved medicine regardless of which       state they live in. To maintain that marijuana is a dangerous, addictive       drug with no medical value is scientifically absurd. Cannabis medicines,       with no effective lethal dose, are far safer than aspirin,       acetaminophen, and most other OTC drugs that kill thousands of Americans       every year.

The Company works with world authorities on phytocannabinoid science       targeting critical illnesses, and adheres to scientific methodologies to       develop, produce and commercialize phytocannabinoid-based pharmaceutical       products. In sum, we are dedicated to the creation of cannabis-based       medicines, both with and without psychoactive properties, to treat       disease and the symptoms of disease, as well as for general health       maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the       meaning of Section 27A of the Securities Act of 1933 and Section 21E of       the Securities Act of 1934. A statement containing works such as       “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,”       “project,” “plan,” or similar phrases may be deemed “forward-looking       statements” within the meaning of the Private Securities Litigation       Reform Act of 1995. Some or all of the events or results anticipated by       these forward-looking statements may not occur. Factors that could cause       or contribute to such differences include the future U.S. and global       economies, the impact of competition, and the Company’s reliance on       existing regulations regarding the use and development of cannabis-based       drugs. Cannabis Science, Inc. does not undertake any duty nor does it       intend to update the results of these forward-looking statements.

 

 

          Contacts

Cannabis Science Inc. Dr. Robert J. Melamede, 1-888-889-0888 begin_of_the_skype_highlighting            1-888-889-0888     end_of_the_skype_highlighting President       & CEO info@cannabisscience.com http://www.cannabisscience.com/

Share

One comment on “Cannabis Science Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with Its Team of FDA Specialists

  • Jeffrey

    Thank you, We will strive to post new info weekly, Please share with patients, family & friends

    Thanks Again & Be Safe,

    Jeffrey Kennedy

Leave a Reply

Your email address will not be published. Required fields are marked *

Connect With Us Online


Follow Us On Twitter

Shopping Cart

Your shopping cart is empty
Visit the shop

Latest Posts

Hide me
Sign up below to join my Email Newsletter
Email:
Show me